The latest announcement is out from Rhythm Biosciences Ltd. ( (AU:RHY) ).
Rhythm Biosciences Ltd has acquired Genetype business assets, significantly enhancing its market position by integrating genetic and proteomic technologies. This strategic acquisition is expected to transform Rhythm into a commercial organization, offering multi-disease predictive risk assessments and accelerating the development of the ColoSTAT® assay, ultimately creating commercial revenue opportunities and enhancing shareholder value.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is a transformative, predictive cancer diagnostics technology company. The company focuses on developing blood-based clinical diagnostics, including the ColoSTAT® assay for colorectal cancer detection and has recently expanded its capabilities with the acquisition of Genetype, a leader in genetic-integrated risk assessment.
YTD Price Performance: -3.33%
Average Trading Volume: 361,673
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$25.24M
For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.